Brind.

Pablo Legorreta was named the founder and CEO of Royalty Pharma, which provides funding in exchange for royalty rights.

9 reports, 4 independent Updated Sep 15
Gone quiet Reached 2 outlets in its first 24 hours
Reports
9
Developments
4
Repetition
56%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Pablo Legorreta was named the founder and CEO of Royalty Pharma, which provides funding in exchange for royalty rights.

Who's involved

What this event is mainly about
Royalty PharmaPablo Legorreta

How it developed

Newest first. Tap a step to see who reported it.
  1. Royalty Pharma announces partnerships with Blood Cancer United and corporate support for TAP.1 source
  2. Royalty Pharma's CEO, Pablo Legorreta, established the company's royalty funding model.1 source
  3. Legorreta confirmed Royalty Pharma's funding model amid financial inquiries from Morgan Stanley and Bank of America.1 source
  4. Pablo Legorreta, the CEO of Royalty Pharma, is leading the development of a portfolio of RAS inhibitor therapies.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • prnewswire.com
  • manilatimes.net
  • GlobeNewswireZenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of
  • GlobeNewswireRoyalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of I
  • StockStory5 Insightful Analyst Questions From Royalty Pharma’s Q2 Earnings Call Royalty Pharma’s Q2 results were met with a negative market reaction, as revenue growth of 7.7% fell short of Wall Street expecta
  • GlobeNewswireRoyalty Pharma Reports Second Quarter 2025 Results Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $364 million Raised fu
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet